Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer

Hiroyasu Yasuda, Mutsuo Yamaya, Katsutoshi Nakayama, Takahiko Sasaki, Satoru Ebihara, Akio Kanda, Masanori Asada, Daisuke Inoue, Tomoko Suzuki, Tatsuma Okazaki, Hidenori Takahashi, Motoki Yoshida, Tomohiro Kaneta, Kota Ishizawa, Shinsuke Yamanda, Naoki Tomita, Miyako Yamasaki, Akiko Kikuchi, Hiroshi Kubo, Hidetada Sasaki

Research output: Contribution to journalArticlepeer-review

117 Citations (Scopus)

Abstract

Purpose: To investigate the efficacy and safety of nitroglycerin plus vinorelbine and cisplatin in patients with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) as the experimental arm for the next phase III trial. Patients and Methods: One hundred twenty patients with stage IIIB/IV NSCLC were randomly assigned to vinorelbine 25 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1, with transdermally applied nitroglycerin (25 mg/patient daily for 5 days; arm A) or with placebo patch (arm B) every 3 weeks for a maximum of four cycles in a double-blind and controlled trial. Primary efficacy end points were the best confirmed response rate and time to disease progression (TTP). Results: The response rate in arm A (72%; 43 of 60 patients) was significantly higher than that for patients in arm B (42%; 25 of 60 patients; P < .001). Median TTP in arm A was longer than that in arm B (327 v 185 days). No severe adverse effect was recognized for either arm. The rate of grade 1 to 2 headache in arm A (30%; 18 of 60 patients) was significantly higher than that in arm B (2%; one of 60 patients; P < .001, χ2 test). Conclusion: Use of nitroglycerin combined with vinorelbine and cisplatin may improve overall response and TTP in patients with stage IIIB/IV NSCLC. The arm A regimen is being evaluated in a large phase III trial.

Original languageEnglish
Pages (from-to)688-694
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number4
DOIs
Publication statusPublished - 2006 Feb 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this